Product Description
Clazakizumab is a genetically engineered humanized immunoglobulin G1 (IgG1) mAb that binds to human IL-6 (Sourced from: https://clinicaltrials.gov/ct2/show/NCT03744910)
Mechanisms of Action: IL6 Inhibitor
Novel Mechanism: No
Modality: Antibody
Route of Administration: Subcutaneous,Intravenous
FDA Designation: None *
Approval Status: Not Approved
Approved Countries: None
Approved Indications: None
Known Adverse Events: None
Company: CSL Behring
Company Location:
Company CEO:
Additional Commercial Interests: None
Clinical Description
Countries in Clinic: Argentina, Australia, Austria, Belgium, Bulgaria, Canada, China, Croatia, Denmark, Estonia, France, Germany, Greece, Hong Kong, Hungary, Israel, Italy, Japan, Korea, Latvia, Lithuania, Mexico, Norway, Poland, Portugal, Romania, Singapore, Slovakia, Spain, Sweden, Taiwan, Thailand, Turkey, United Kingdom, United States, Unknown Location
Active Clinical Trial Count: 5
Highest Development Phases
Phase 3: Atherosclerosis|Coronary Artery Disease|Kidney Diseases|Kidney Failure, Chronic|Kidney Transplant|Myocardial Infarction
Phase 2: Inflammation
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
|---|---|---|---|---|---|
| POSIBIL6ESKD | P3 |
Recruiting |
Atherosclerosis|Kidney Failure, Chronic |
2029-08-30 |
|
| CSL300_2301 | P3 |
Unknown Status |
Kidney Diseases |
2029-04-30 |
|
| jRCT2061240044 | P3 |
Not yet recruiting |
Coronary Artery Disease|Kidney Diseases|Myocardial Infarction |
2029-04-30 |
|
| 2018-003682-34 | P3 |
Active, not recruiting |
Kidney Transplant |
2027-04-19 |